Initial study population including 1235 consecutive patients diagnosed with ET or PV for which at least 1 DNA sample was available*
| MPN . | JAK2 (V617F) mutated (%) . | JAK2 exon 12 mutated (%) . | MPL exon 10 mutated (%) . | CALR exon 9 mutated (%) . | Nonmutated JAK2/MPL/CALR (%) . | All genotypes . |
|---|---|---|---|---|---|---|
| ET | 466 (62) | — | 28 (4) | 176 (24) | 75 (10) | 745 |
| PV | 468 (96) | 22 (4) | — | — | — | 490 |
| All patients | 1235 |
| MPN . | JAK2 (V617F) mutated (%) . | JAK2 exon 12 mutated (%) . | MPL exon 10 mutated (%) . | CALR exon 9 mutated (%) . | Nonmutated JAK2/MPL/CALR (%) . | All genotypes . |
|---|---|---|---|---|---|---|
| ET | 466 (62) | — | 28 (4) | 176 (24) | 75 (10) | 745 |
| PV | 468 (96) | 22 (4) | — | — | — | 490 |
| All patients | 1235 |
Population included patients followed at the Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Italy, between 1980 and 2012.